Skip to content

KALARIS THERAPEUTICS, INC.

KLRS

CIK 0001754068

← back to feed
Revenue (TTM)
$165K
Q1 May 2026
Net Income (TTM)
−$44.3M
+37.2% YoY Q1 May 2026
EPS Diluted (TTM)
−$4.23
+94.5% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-28,596.4%
Q1 May 2026
Net Margin
-26,846.1%
Q1 May 2026
Free Cash Flow (TTM)
−$55.86M
Q1 May 2026
Cash
$34.43M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
23.79M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings